DSM Receives Best Contract Manufacturing Organization Award from Biopharma Asia
PARSIPPANY, N.J., April 3, 2012 /PRNewswire/ -- DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM N.V. (NYSE, Euronext: DSM KON) was recognized at the 2nd Annual Biopharma Asia Industry Awards in Singapore for their end-to-end suite of customer solutions, spearheading contract manufacturing innovations and raising standards in the region.
The awards program was launched to celebrate Asia's evolving importance as a destination for life science partnerships and business activities. According to the sponsors, the award aims to recognize the best contract manufacturing organization (CMO) that has demonstrated an ongoing commitment to improve their contract manufacturing services in Asia and in reducing lead times for its customers. DSM BioSolutions, the business unit of DSM Pharmaceutical Products recognized, offers CMO development and manufacturing services related to cGMP microbial fermentation with production platforms developed for a variety of micro-organisms ranging from pharmaceutical proteins to metabolites and enzymes.
Additionally, DSM was considered for their ability to scale-up to large scale fermentors, resulting in significantly lower cost-of-goods (COGS); the expertise of the DSM Biotechnology Center, with over 450 scientists active in the field of genetics, strain development, process and analytical development; and a veritable "one-stop-shop" in biopharmaceutical development and manufacturing, including cGMP green chemistry; mammalian cell based culture production of antibodies and proteins; as well as finishing of high-end biopharmaceuticals.
Alexander Wessels, CEO of DSM Pharmaceutical Products, stated, "DSM is committed to providing solutions for the future of biopharmaceutical manufacturing, and DSM is driving sustainability and 'peace of mind' for both small and large molecule production across our pharma offering." Villaume Kal, Vice President of DSM BioSolutions, commented, "We are honored to receive this distinction by demonstrating our qualifications to Biopharma Asia as a global customer-oriented organization."
DSM also gave presentations on dealing with high risks in biopharmaceutical development and technologies for microbial fermentation at the BioPharma Asia Convention 2012. The Biopharma Asia Industry Awards are given by Terrapinn Media Ltd., a global business media company.
DSM – Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 22,000 employees deliver annual net sales of about EUR 9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsmbiosolutions.com and www.dsm.com
This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.
For more information:
Director, Marketing and Communications
DSM Pharmaceutical Products
tel. +1 973 257 8160
tel. +31 15 279 2173
SOURCE DSM Pharmaceutical Products
More by this Source
DSM and Tunitas Therapeutics Sign Agreement to Develop Lead Allergy Therapeutic
Dec 03, 2013, 11:00 ET
DSM and Opthea Sign Agreement to Manufacture Opthea's Lead Product for Eye Disease
Oct 29, 2013, 17:55 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.